1
|
Huho AN, Issaq N, Iacobas I, Elghetany TM, López-Terrada D, Fisher KE, Punia JN. A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. Pediatr Dev Pathol 2018; 21:100-104. [PMID: 29187020 DOI: 10.1177/1093526617698601] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Pediatric chronic myelogenous leukemia is uncommon. We report a pediatric patient with chronic myelogenous leukemia presenting with a normal white blood cell count and no circulating immature myeloid cells. The patient presented with extreme thrombocytosis (platelet count range: 2175-3064 × 109/L) noted incidentally. No splenomegaly was found. Examination of the bone marrow aspirate revealed normal cellularity and normal myeloid: erythroid ratio with marked megakaryocytic hyperplasia. Molecular studies on the bone marrow aspirate detected both the major BCR/ABL1 p210 fusion transcript (9280 copies; p210/ ABL1 ratio: 38.2%) and the minor p190 transcript (below limit of quantitation). The platelet count normalized within 2 weeks after treatment with the second-generation tyrosine kinase inhibitor dasatinib. Follow-up after 3 months revealed a 1.87 log reduction in p210 transcripts compared to diagnosis and no detectable p190 transcripts. This case highlights the need to include BCR/ABL1 fusion testing to accurately diagnose pediatric patients presenting with isolated thrombocytosis.
Collapse
Affiliation(s)
- Albert N Huho
- 1 Department of Pathology & Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA
| | - Niveen Issaq
- 1 Department of Pathology & Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA
| | - Ionela Iacobas
- 2 Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, Texas, USA
| | - Tarek M Elghetany
- 1 Department of Pathology & Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA
| | - Dolores López-Terrada
- 1 Department of Pathology & Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA
| | - Kevin E Fisher
- 1 Department of Pathology & Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA
| | - Jyotinder N Punia
- 1 Department of Pathology & Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA
| |
Collapse
|
2
|
ARDERN JC, SPEAK J, HYDE K, HUNT LP, LAWSON R, GORST DW, GEARY CG, LUCAS GS. Molecular analysis in chronic granulocytic leukaemia: location of breakpoints within M-BCR and relationship with presentation platelet counts. ACTA ACUST UNITED AC 2008. [DOI: 10.1111/j.1365-2257.1993.tb00146.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Mondal BC, Bandyopadhyay A, Majumdar S, Mukhopadhyay A, Chandra S, Chaudhuri U, Chakrabarti P, Bhattacharyya S, Dasgupta UB. Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol 2006; 81:845-9. [PMID: 16888785 DOI: 10.1002/ajh.20682] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Molecular breakpoint of the BCR-ABL fusion gene has been characterized for 122 chronic myeloid leukemia patients. Out of 122 cases, 33 b2a2, 69 b3a2, 2 e1a2, and 2 e19a2 cases have been detected. Six coexpressed both b2a2 and b3a2 transcripts. All the coexpressing samples had an A>G polymorphism at the putative splice branchpoint in intron 13. The T>C polymorphism in exon 13, reported to be linked to coexpression, was not present in all the coexpressing patients. No correlation of transcript type with platelet count was detected. Those expressing b2a2 transcript were diagnosed at relatively younger age and with higher white blood cell count, in agreement with other reports. However, the correlation was not statistically significant.
Collapse
MESH Headings
- Adult
- Base Sequence
- DNA Primers
- DNA, Neoplasm/genetics
- DNA, Neoplasm/isolation & purification
- Female
- Fusion Proteins, bcr-abl/genetics
- Gene Expression Profiling
- Genotype
- Humans
- India
- Introns
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Male
- Middle Aged
- Polymorphism, Genetic
- RNA, Neoplasm/genetics
- RNA, Neoplasm/isolation & purification
- Reverse Transcriptase Polymerase Chain Reaction
- Transcription, Genetic
Collapse
Affiliation(s)
- Bama C Mondal
- Department of Biophysics, Molecular Biology and Genetics, University of Calcutta, Kolkata, India
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Inokuchi K. Chronic Myelogenous Leukemia: From Molecular Biology to Clinical Aspects and Novel Targeted Therapies. J NIPPON MED SCH 2006; 73:178-92. [PMID: 16936444 DOI: 10.1272/jnms.73.178] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The critical causative event in chronic myelogenous leukemia (CML) is the fusion of the head of the bcr gene with the body of the abl gene, named bcr/abl gene. This chimeric BCR/ABL molecule transforms primary myeloid cells to leukemic cells and induces a CML-like disease in mice. The mouse CML model expressing the BCR/ABL molecule has provided important new insights into the molecular pathophysiology of CML and has directly answered many questions regarding this disease. Furthermore, numerous clinical studies have demonstrated a correlation between leukemic clinical features and the position of the breakpoint in the BCR gene of the chimeric BCR/ABL gene. Understanding of the molecular pathogenesis of CML has led to the development of several novel therapies. The BCR/ABL molecule is unique oncogeneiety, having ABL tyrosine kinase activity, making it an ideal target for drug development. Subsequent clinical studies now realize the hypothesis that selective inhibition of the abl tyrosine kinase activity using imatinib mesylate might be useful for the treatment of CML. This article reviews the history of BCR/ABL molecular biology, including the CML model mouse, clinical molecular studies and the recent findings of imatinib mesylate and more potent tyrosine kinase inhibitors developed for the treatment of CML.
Collapse
Affiliation(s)
- Koiti Inokuchi
- Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
| |
Collapse
|
5
|
Inokuchi K, Hamaguchi H, Taniwaki M, Yamaguchi H, Tanosaki S, Dan K. Establishment of a cell line with AML1-MTG8, TP53, and TP73 abnormalities from acute myelogenous leukemia. Genes Chromosomes Cancer 2001; 32:182-7. [PMID: 11550287 DOI: 10.1002/gcc.1181] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Gene alterations accumulate during the progression of acute myelogenous leukemia (AML) to a malignant clone. Here, a new myeloid cell line, designated YSK-21, with the balanced t(8;21)(q22;q22) and the unbalanced der(1)t(1;17)(p36;q21), was established. YSK-21 grows well in a medium containing recombinant human granulocyte colony-stimulating factor (rhG-CSF), granulocyte-macrophage colony-stimulating factor (rhGM-CSF), or interleukin-3 (rhIL-3). Molecular analysis using the reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) revealed that t(8;21)(q22;q22) resulted in an AML1-MTG8 fusion transcript. FISH and spectral karyotyping (SKY) in conjunction with G-banding analysis revealed a der(1)t(1;17)(p36;q21) chromosomal translocation, which appeared in the clone developed from the original leukemic cells. Molecular analysis of the TP73 gene on 1p36 and the TP53 gene revealed a deletion of one-allele in TP73 with partial demethylation of another allele in the initial clone of YSK, and a point mutation consisting of an A-->T substitution in codon 288 of the TP53 gene in the developed clone of YSK-21. YSK-21 cells, expressing aberrant AML1-MTG8, TP53, and TP73 protein molecules, may be useful for elucidating the pathophysiology of these aberrant proteins and for studying the der(1)t(1;17)(p36;q21) chromosomal translocation.
Collapse
Affiliation(s)
- K Inokuchi
- Division of Hematology, Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113, Japan.
| | | | | | | | | | | |
Collapse
|
6
|
Yamaguchi H, Inokuchi K, Shinohara T, Dan K. Extramedullary presentation of chronic myelogenous leukemia with p190 BCR/ABL transcripts. CANCER GENETICS AND CYTOGENETICS 1998; 102:74-7. [PMID: 9530344 DOI: 10.1016/s0165-4608(97)00298-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We present here a rare case of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia having p190 BCR/ABL with a malignant clinical picture of extramedullary blast crisis at onset, followed by rapid evolution to bone-marrow blast crisis. The patient was a 44-year-old woman presenting with leukocytosis and multiple lymph-node swelling in the neck. Lymph-node biopsy revealed a myeloperoxidase-positive blastoma with cell-surface markers of myeloid and T-lymphoid lineages. Fluorescence in situ hybridization and the reverse transcription polymerase chain reaction detected a minor BCR breakpoint but failed to detect a major BCR breakpoint. By single-strand conformation polymorphism and direct sequencing, no alteration in the TP53 gene was found, and no additional chromosomal abnormalities other than Ph were identified. The present case suggests that p190 BCR/ABL is associated with the aggressive course of the disease.
Collapse
Affiliation(s)
- H Yamaguchi
- Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
| | | | | | | |
Collapse
|
7
|
Abstract
The BCR-ABL hybrid gene, the main product of the t(9;22)(q34;q11) translocation, is found in the leukaemic clone of at least 95% of CML patients. The fusion protein encoded by BCR-ABL varies in size, depending on the breakpoint in the BCR gene. Three breakpoint cluster regions have been characterized to date: major (M-bcr), minor (m-bcr) and micro (mu-bcr). The overwhelming majority of CML patients have a p210 BCR-ABL gene (M-bcr), whose mRNA transcripts have a b3a2 and/or a b2a2 junction. There is apparently no significant difference between patients with a 5' or a 3' M-bcr breakpoint, except maybe for a slight predominance of b3a2-expressing cases among those with increased platelet counts (ET-like syndrome). The smallest of the fusion proteins, p190BCR-ABL, (m-bcr breakpoint) is principally associated with Ph-positive ALL. Rare cases of CML are due to a p190-type of BCR-ABL gene and, in these, the disease tends to have a prominent monocytic component, resembling CMML. CML resulting from a p230 BCR-ABL gene (mu-bcr breakpoint) is also rare, and has been associated with the CNL variant and/or with marked thrombocytosis. Exceptional CML cases have been described with BCR breakpoints outside the three defined cluster regions, or with unusual breakpoints in ABL resulting in BCR-ABL transcripts with b2a3 or b3a3 junctions, or with aberrant fusion transcripts containing variable lengths of intronic sequence inserts. The reciprocal ABL-BCR gene found in the derivative 9q+ chromosome of the t(9;22) is transcriptionally active in nearly two-thirds of CML patients but has not been shown so far to have a functional role in CML. 'Ph-negative CML' comprises cases of typical CML in whom the BCR-ABL gene can be detected by molecular methods and others who are genuinely BCR-ABL negative and usually have an atypical disease phenotype.
Collapse
Affiliation(s)
- J V Melo
- Department of Haematology, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom
| |
Collapse
|
8
|
Viniou NA, Matzourani M, Yataganas X, Meletis J, Pangalis G, Loukopoulos D. Correlation of the site of M-bcr breakpoint with chronic phase duration, blastic crisis lineage and thrombocytosis in Ph1-positive chronic myelogenous leukemia. Leuk Lymphoma 1995; 18:335-9. [PMID: 8535202 DOI: 10.3109/10428199509059627] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The breakpoints on chromosome 22 in CML occur within a 5.8 kb region called the Major breakpoint cluster region (M-bcr). DNA mapping within the M-bcr region was performed in 41 long term followed Ph1-positive CML patients using the Southern blot technique. The purpose of this study was to determine whether localization of M-bcr breakpoint correlates with the length of chronic phase of the disease, blastic crisis lineage and thrombocytosis at the time of initial diagnosis. Our results fail to indicate any correlation between breakpoint localization and duration of chronic phase, blastic crisis lineage and platelet count at diagnosis.
Collapse
MESH Headings
- Blast Crisis
- Cell Lineage/genetics
- Chromosomes, Human, Pair 22
- Follow-Up Studies
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Multigene Family
- Platelet Count
- Thrombocytosis/blood
- Thrombocytosis/genetics
- Thrombocytosis/pathology
- Translocation, Genetic
Collapse
Affiliation(s)
- N A Viniou
- First Department of Internal Medicine, National and Kapodistrian University, Laikon General Hospital, Athens, Greece
| | | | | | | | | | | |
Collapse
|
9
|
Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89:546-54. [PMID: 7734353 DOI: 10.1111/j.1365-2141.1995.tb08362.x] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Two hundred and nineteen cases of Ph+ve CML and 15 Ph-ve, BCR+ve CML cases have been analysed to determine the breakpoint site and its relationship to clinical features, cytogenetic response, duration of chronic phase and survival. 119 cases have had RNA analysis performed to determine the type of BCR/ABL transcript and have also been analysed in a similar way. Presenting features at diagnosis including age, sex, white-cell count and platelet count showed no significant difference for those with 5' and 3' breakpoints and those with either b2a2 or b3a2 BCR/ABL transcripts. However, in a subgroup of patients whose presenting white-cell count was < 100 x 10(9)/l, those with b3a2 transcript did have a significantly higher platelet count. Analysis by Sokal risk grouping showed no difference for 5' or 3' breakpoints but a trend for lower stage among those with b2a2 transcripts. No correlation was found either for genomic breakpoint site or BCR/ABL RNA transcript in terms of duration of chronic phase or survival. When stratified by randomized therapy, either interferon-alpha or standard chemotherapy, no difference was noted in relation to genomic breakpoint site or BCR/ABL transcript. Cytogenetic response was not related to the molecular findings.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Base Sequence
- Female
- Fusion Proteins, bcr-abl/genetics
- Humans
- Interferon-alpha/therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/genetics
- Male
- Middle Aged
- Molecular Sequence Data
- Oncogene Proteins/genetics
- Prognosis
- Prospective Studies
- Protein-Tyrosine Kinases
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins c-bcr
- RNA Splicing
- RNA, Messenger/genetics
- RNA, Neoplasm/genetics
- Survival Rate
- Time Factors
- Transcription, Genetic/genetics
Collapse
Affiliation(s)
- P Shepherd
- Department of Medicine, Western General Hospital, Edinburgh
| | | | | | | |
Collapse
|
10
|
Stewart M, Cox G, Reifel-Miller A, Kim S, Westbrook C, Leibowitz D. A novel transcriptional suppressor located within a downstream intron of the BCR gene. J Biol Chem 1994. [DOI: 10.1016/s0021-9258(17)34133-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
11
|
Miyake K, Inokuchi K, Dan K, Nomura T. Expression of the DCC gene in myelodysplastic syndromes and overt leukemia. Leuk Res 1993; 17:785-8. [PMID: 8371579 DOI: 10.1016/0145-2126(93)90113-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
To evaluate the molecular events in the genome that are associated with myelodysplastic syndromes (MDS) and the development of leukemia, we investigated the expression of the deleted in colorectal carcinoma (DCC) gene by the reverse transcriptase-polymerase chain reaction (RTPCR) method in 24 MDS cases and in 7 overt leukemia cases that progressed from MDS. Expression of the DCC gene was absent or extremely reduced in 2 of the 24 MDS cases, and those 2 cases developed overt leukemia within 6 months. Moreover, in 5 of the 7 cases of overt leukemia that developed from MDS, expression of the DCC gene was absent or extremely reduced. These findings suggest that inactivation of the DCC gene may be the late event that triggers the progression of MDS to leukemia.
Collapse
Affiliation(s)
- K Miyake
- Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
| | | | | | | |
Collapse
|
12
|
Inokuchi K, Nomura T. The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myelogenous leukemia. Leuk Lymphoma 1993; 10:9-15. [PMID: 8374529 DOI: 10.3109/10428199309147351] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Formation of the Philadelphia (Ph1) chromosome, which contains the hybrid bcr-abl gene, is thought to be the initial event in chronic myelogenous leukemia (CML). The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots, and the splicing pattern were also determined the species of the fused bcr-abl mRNA in 79 CML cases using the polymerase chain-reaction procedure (RT-PCR). The location of the breakpoint within the bcr locus was assigned to one of five zones. Breakpoints in zones 1 and 2 were grouped as 5', and those in zones 3, 4 and 5 as 3'. Nine patients had 5' breakpoints and 13 patients had 3' breakpoints. The platelet counts of 3' patients were significantly higher than those of 5' patients (1395 vs 274 x 10(9)/L; p < 0.03). The megakaryocyte counts from bone marrow histological sections in 3' patients (n = 12) and 5' patients (n = 7) were 63.4/mm2 and 19.5/mm2, with a significant difference at p < 0.006. The mean number of megakaryocyte progenitor cells assayed by in vitro cloning was 128.3/2 x 10(5) bone marrow cells for 3' patients (n = 7) compared with 46.3 for 5' patients (n = 4). Using the RT-PCR technique, the bcr exon 2/abl exon 2 fused mRNA (b2-a2) was detected in 18 patients, the bcr exon 3/abl exon 2 fused mRNA (b3-a2) was detected in 45 patients, and both types of mRNA were detected in 16 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
MESH Headings
- Base Sequence
- Blood Platelets/physiology
- Fusion Proteins, bcr-abl/genetics
- Genes, abl
- Hematopoiesis
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Megakaryocytes
- Molecular Sequence Data
- Platelet Count
- RNA, Messenger/analysis
- RNA, Neoplasm/analysis
Collapse
Affiliation(s)
- K Inokuchi
- Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
| | | |
Collapse
|
13
|
Mills KI. The relationship between the location of the breakpoint within the M-bcr and clinical parameters. Leuk Lymphoma 1993; 11 Suppl 1:73-9. [PMID: 8251922 DOI: 10.3109/10428199309047868] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The Philadelphia chromosome (t9;22)(q34;q11) is a characteristic abnormality in chronic myeloid leukemia. In greater than 95% of the cases, the breakpoint occurs with the M-bcr region of the BCR gene on chromosome 22. Several studies have attempted to correlate the location of the breakpoint within the M-bcr with a clinical parameter. The majority of studies have examined the relationship between the site of breakpoint and the median chronic phase duration (CPD). Some studies have reported a correlation, with 5' breakpoint patients who have a longer median CPD than patients with a 3' breakpoint. However, other groups have reported that no correlation exists. Furthermore, data from some of the latter groups have suggested that a correlation may exist with the lineage of blast crisis which developed and 3' breakpoint patients had a higher than expected number of lymphoid blast crisis. A correlation between high platelet counts at diagnosis and patients with a 3' breakpoint or those who expressed a b3-a2 BCR-ABL mRNA has also been described. No consistent conclusion from any of these studies can be drawn. This may due, in part, to some degree of patient and sample selection, although environmental, genetic or life-style factors may also contribute.
Collapse
MESH Headings
- Biomarkers, Tumor/genetics
- Blast Crisis/classification
- Blast Crisis/genetics
- Blast Crisis/mortality
- Chromosome Aberrations
- Cohort Studies
- Female
- Fusion Proteins, bcr-abl/genetics
- Humans
- Italy/epidemiology
- Japan/epidemiology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myeloid, Chronic-Phase/genetics
- Male
- Platelet Count
- Prognosis
- Scotland/epidemiology
- Survival Analysis
Collapse
Affiliation(s)
- K I Mills
- Department of Haematology, Glasgow Royal Infirmary, Scotland
| |
Collapse
|
14
|
Futaki M, Inokuchi K, Matsuoka H, Miyake K, Dan K, Nomura T. Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia. Leuk Res 1992; 16:1071-5. [PMID: 1434743 DOI: 10.1016/0145-2126(92)90045-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases. We found no correlation between the two types of bcr-abl mRNA and the chronic phase duration or survival. The DNA from 12 of 20 chronic phase patients and all five blastic phase patients showed transforming activity. Although there was no difference in the positive rate of transforming activity among the two mRNA-type groups, the blastic phase patients showed a tendency to have higher transforming activity.
Collapse
MESH Headings
- 3T3 Cells
- Adult
- Aged
- Animals
- Base Sequence
- Cell Transformation, Neoplastic
- Female
- Fusion Proteins, bcr-abl/genetics
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Male
- Mice
- Mice, Nude
- Middle Aged
- Molecular Sequence Data
- Prognosis
- RNA, Messenger
Collapse
Affiliation(s)
- M Futaki
- Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
15
|
Opalka B, Wandl UB, Kloke O, Beer U, Seeber S, Niederle N. No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CML. Leuk Res 1992; 16:937-9. [PMID: 1405723 DOI: 10.1016/0145-2126(92)90039-a] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
In chronic myelogenous leukemia (CML) malignant cells are characterised by the Philadelphia chromosome (Ph), resulting from a translocation t(9;22). The position of the breakpoint within the major breakpoint cluster region (M-bcr) on chromosome 22 has been shown to correlate with the clinical course of the disease or, more recently, thrombopoietic activity. We have therefore determined the breakpoint localisation in 53 Ph-positive CML patients. Following the 5'/3'-region definition of Inokuchi et al. Leukemia Research 15, 1067 (1991) [1], 22 of our patients have 5' and 31 of our patients have 3' orientated breaks. No correlation was found between platelet counts and breakpoint localisation.
Collapse
MESH Headings
- Chromosome Aberrations/genetics
- Chromosomes, Human, Pair 22
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Platelet Count
- Prognosis
Collapse
Affiliation(s)
- B Opalka
- Department of Internal Medicine, West German Cancer Centre Essen, University of Essen Medical School
| | | | | | | | | | | |
Collapse
|